Celyad SA

Celyad SA is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Celyad SA is not a good value stock. Celyad SA is not a good growth stock. Celyad SA is not very popular among insiders. Celyad SA is a mediocre stock to choose.
Log in to see more information.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the identification and dev...
CYAD Fundamental Data by TradingView

News

Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders

Globe Newswire MONT-SAINT-GUIBERT, Belgium, Aug. 24, 2023 (GLOBE NEWSWIRE) -- regulated information / inside information - Celyad Oncology SA (Celyad or the Company) today announced that it has obtained commitments from an affiliate of Fortress Investment Group (such affiliate, Fortress), Tolefi SA (Tolefi), and ...\n more…

Celyad Oncology reports Q1 results
Celyad Oncology reports Q1 results

SeekingAlpha.com: All News Celyad Oncology press release (CYAD): Q1 As of March 31, 2023, the Company had cash and cash equivalents of €9.2 million ($10.0 million).Net cash burn during the first quarter of...\n more…

Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq

Globe Newswire MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the Company), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that its Board of Directors has approved the ...\n more…

Celyad Oncology reports first quarter 2023 financial results and recent business highlights
Celyad Oncology reports first quarter 2023 financial results and recent business highlights

Globe Newswire Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneouslyPublication of results from the THINK trial, which provided proof-of-concept of our NKG2D-based CAR T-cell approach MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- ...\n more…

Celyad Oncology receives non-compliance letter from Nasdaq
Celyad Oncology receives non-compliance letter from Nasdaq

Seeking Alpha - Healthcare Celyad Oncology (CYAD) received a letter on April 19th from the Nasdaq informing that the company's minimum closing bid price per share was below $1 for a period of 30 consecutive days...\n more…

Celyad Oncology announces receipt of Nasdaq notice
Celyad Oncology announces receipt of Nasdaq notice

Globe Newswire MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the Company), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the Letter) on March 31, 2023 from The Nasdaq ...\n more…